Trials / Unknown
UnknownNCT01959061
Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
Raltitrexed and Oxaliplatin and Lipiodol Transcatheter Arterial Chemoembolization for Advanced Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 320 (estimated)
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of Raltitrexed for advanced colorectal cancer
Detailed description
evaluate the efficacy and safety of Raltitrexed and oxaliplatin and lipiodol transcatheter arthrial chemoembolization for in refractory colorectal carcinoma with liver metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Raltitrexed | 4mg, every 4 weeks,transhepatic arterial infusion |
| DRUG | Oxaliplatin | 100\~150mg, every 4 weeks, transhepatic arterial infusion |
| DRUG | lipiodol | 5-20ml, every 4 weeks, hepatic artery embolization |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2013-10-09
- Last updated
- 2017-03-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01959061. Inclusion in this directory is not an endorsement.